Hec-50 Xenograft Model Service for Endometrial Cancer

The Hec-50 xenograft model offers a robust preclinical platform for evaluating therapeutic candidates against aggressive, high-grade endometrial carcinoma, enabling researchers to assess tumor growth dynamics, drug response, and biomarker expression in an in vivo setting. At Alfa Cytology, we specialize in delivering validated, high-quality Hec-50 xenograft models tailored to support your preclinical research programs, from early-stage pharmacology studies to comprehensive efficacy and toxicity assessments.

Overview of Hec-50 Xenograft Model for Endometrial Cancer

The Hec-50 cell line was originally established from the ascitic fluid of a patient diagnosed with recurrent Grade 3 endometrioid adenocarcinoma of the uterine corpus. As a representative of Type II endometrial cancer, Hec-50 exhibits molecular characteristics distinct from the more common Type I subtype, including TP53 mutations and absence of PTEN alterations, making it a clinically relevant model for studying aggressive, hormone-independent disease progression. The cell line demonstrates epithelial-like morphology and maintains tumorigenic potential when implanted into immunocompromised murine hosts, forming xenografts that recapitulate key histological and molecular features of the original high-grade tumor.

In preclinical oncology research, the Hec-50 xenograft model serves as a critical tool for investigating tumor biology, evaluating novel therapeutic agents, and understanding mechanisms of drug resistance in endometrial carcinoma. The model has been extensively utilized in studies assessing chemotherapy sensitivity, targeted therapy efficacy, and combination treatment strategies. Xenografts derived from Hec-50 cells typically exhibit rapid growth kinetics and maintain histopathological characteristics consistent with poorly differentiated endometrioid adenocarcinoma, providing researchers with a reliable platform for translational studies aimed at improving patient outcomes in high-grade endometrial cancer.

Figure 1. PTPN18 was highly expressed in EC cells. (Suo, Shiqi, et al., 2025)

Cell Line Information: Hec-50

The Hec-50 cell line (also designated as HEC-50B) represents a well-characterized human endometrial cancer model derived from a Japanese patient with recurrent Grade 3 endometrioid adenocarcinoma. The following table summarizes the key characteristics and technical specifications of this cell line:

Our Services

Alfa Cytology provides comprehensive Hec-50 xenograft model services designed to accelerate your preclinical drug development pipeline. Our experienced team ensures rigorous quality control, standardized protocols, and customizable study designs to meet your specific research objectives, delivering reliable data to support informed decision-making in endometrial cancer therapeutic development.

Workflow of Hec-50 Xenograft Model Construction

The construction of Hec-50 xenograft models follows a systematic, multi-step process designed to ensure reproducible tumor growth and reliable experimental outcomes. Each stage is carefully monitored to maintain model integrity and data quality.

1. Cell Culture and Preparation: Hec-50 cells are maintained in Eagle's minimal essential medium supplemented with 15% fetal bovine serum under standard culture conditions (37 degrees C, 5% CO2). Cells are harvested during the logarithmic growth phase using 0.1% trypsin-0.02% EDTA, washed, and resuspended in sterile phosphate-buffered saline or serum-free medium at the appropriate concentration for injection.
2. Quality Control and Authentication: Prior to inoculation, cell viability is assessed using trypan blue exclusion (target viability >95%). Cell identity is confirmed through STR profiling to ensure authenticity and exclude cross-contamination. Mycoplasma testing is performed to guarantee cell line purity.
3. Animal Selection and Preparation: Immunocompromised mouse strains (typically BALB/c nude or NOD-SCID) are selected based on study requirements. Animals are acclimatized for 5-7 days under pathogen-free conditions with controlled temperature, humidity, and light-dark cycles.
4. Tumor Cell Inoculation: Hec-50 cells are subcutaneously injected into the flank region of recipient mice at a standardized density (typically 1-5 x 10^6 cells per site in 100-200 microL volume). For orthotopic models, cells may be injected into the uterine horn to mimic anatomical tumor growth patterns.
5. Tumor Monitoring and Measurement: Tumor development is monitored twice weekly using digital calipers. Tumor volume is calculated using the formula V = (length x width^2) / 2. Mice are randomized into treatment groups once tumors reach 100-200 mm^3 to ensure baseline uniformity.
6. Treatment Administration and Endpoint Analysis: Test compounds are administered according to predefined protocols (oral gavage, intraperitoneal, or intravenous injection). Tumor growth, body weight, and clinical signs are recorded throughout the study. At endpoint, tumors are excised, weighed, and processed for histopathology, immunohistochemistry, and molecular analysis.

Figure 2: Schematic workflow illustrating the derivation and construction of the Hec-50 Xenograft Model at Alfa Cytology.

Case Study-Hec-50 Xenograft Model Development

In a representative preclinical study, the Hec-50 xenograft model was successfully established in immunocompromised mice to evaluate the efficacy of novel therapeutic agents against high-grade endometrial carcinoma. Tumor-bearing mice demonstrated consistent engraftment rates with palpable masses appearing within 7-10 days post-inoculation. The model exhibited progressive tumor growth with doubling times consistent with aggressive Type II endometrial cancer characteristics. Treatment cohorts received varying dosing regimens of investigational compounds, with tumor growth inhibition, survival outcomes, and biomarker modulation serving as primary and secondary endpoints. Comprehensive histopathological analysis confirmed maintenance of endometrioid adenocarcinoma morphology within xenograft tissues, while immunohistochemical staining validated relevant protein expression patterns. This case study demonstrates the utility of the Hec-50 model as a reliable platform for preclinical pharmacological evaluation, with data packages supporting further translational development. (Specific quantitative data available upon request for customized study proposals.)

Why Choose Alfa Cytology?

Alfa Cytology stands as a trusted partner for preclinical oncology research, offering specialized expertise in endometrial cancer model development and comprehensive study execution.

• Expertise in Type II endometrial cancer models with validated Hec-50 xenograft protocols and extensive historical data.
• Rigorous quality assurance including STR authentication, mycoplasma screening, and standardized tumor monitoring procedures.
• Flexible study designs accommodating subcutaneous, orthotopic, and patient-derived xenograft (PDX) model configurations.
• Comprehensive endpoint analysis encompassing tumor growth kinetics, pharmacokinetic profiling, histopathology, and biomarker assessment.
• Dedicated project management ensuring transparent communication, timely reporting, and adherence to predefined milestones.
• Competitive timelines and cost-effective solutions without compromising scientific rigor or data integrity.

Contact us

Ready to advance your endometrial cancer research program? Contact us today to discuss your specific project requirements and discover how Alfa Cytology's Hec-50 Xenograft Model Service can accelerate your preclinical development. Our scientific team is prepared to reach out to you within 24 hours to provide detailed study proposals and customized solutions tailored to your therapeutic objectives.

For research use only. Not intended for any clinical use.